Most common sites of metastasis of urothelial carcinoma (UC) are lungs, liver, lymph nodes and bone. Pembrolizumab, a humanized monoclonal antibody directed against programmed cell death protein-1 (PD-1), represents an effective second-line therapy for advanced UC. Radiotherapy has been shown to induce a mechanism of immunogenic cell death (ICD) resulting in immune memory and advantageous systemic effects. We present the first case of breast metastasis (BM) from a UC described in literature who had an exceptional response to second-line therapy with pembrolizumab in association with radiotherapy, showing the efficacy of combining immunotherapy and radiotherapy even in patients with atypical metastatic sites.

Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma : A case report / G. Bonfante, E. Fantinel, C. Masini, F. Bergamaschi, S. Micali, B. Rocco. - In: UROLOGY CASE REPORTS. - ISSN 2214-4420. - 34(2021), pp. 101444.1-101444.3. [10.1016/j.eucr.2020.101444]

Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma : A case report

B. Rocco
2021

Abstract

Most common sites of metastasis of urothelial carcinoma (UC) are lungs, liver, lymph nodes and bone. Pembrolizumab, a humanized monoclonal antibody directed against programmed cell death protein-1 (PD-1), represents an effective second-line therapy for advanced UC. Radiotherapy has been shown to induce a mechanism of immunogenic cell death (ICD) resulting in immune memory and advantageous systemic effects. We present the first case of breast metastasis (BM) from a UC described in literature who had an exceptional response to second-line therapy with pembrolizumab in association with radiotherapy, showing the efficacy of combining immunotherapy and radiotherapy even in patients with atypical metastatic sites.
Breast metastasis; Immune checkpoint inhibitor; Metastatic urothelial carcinoma; PD-1; Radiotherapy
Settore MED/24 - Urologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
Bonfante 1-s2.0-S2214442020303338-main.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 2.97 MB
Formato Adobe PDF
2.97 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/876230
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact